{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=55", "query": { "condition": "Non-small Cell Lung Cancer (NSCLC)", "page": 55 }, "page_size": 10 }, "pagination": { "page": 55, "page_size": 10, "total_count": 3563, "total_pages": 357, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=56&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancer+%28NSCLC%29&page=54&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T12:46:31.584Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01574222", "title": "A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "autologous dendritic cell adenovirus CCL21 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 1, "start_date": "2011-10-01", "completion_date": "2017-03-01", "has_results": false, "last_update_posted_date": "2018-01-18", "last_synced_at": "2026-10-20T12:46:31.584Z", "location_count": 1, "location_summary": "West Los Angeles, California", "locations": [ { "city": "West Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01574222" }, { "nct_id": "NCT05493501", "title": "Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "Aumolertinib monotherapy", "type": "DRUG" }, { "name": "Osimertinib monotherapy", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EQRx International, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-12-14", "completion_date": "2023-08-31", "has_results": true, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-10-20T12:46:31.584Z", "location_count": 8, "location_summary": "Springdale, Arkansas • Hollywood, Florida • Pembroke Pines, Florida + 5 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Florham Park", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05493501" }, { "nct_id": "NCT01074177", "title": "Understanding Mechanisms of Acquired Resistance to BIBW2992", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non-small Cell Lung Cancer", "EGFR Mutations" ], "interventions": [ { "name": "BIBW 2992", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2011-02", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2018-03-09", "last_synced_at": "2026-10-20T12:46:31.584Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074177" }, { "nct_id": "NCT03693300", "title": "A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 117, "start_date": "2019-04-16", "completion_date": "2023-04-21", "has_results": true, "last_update_posted_date": "2024-06-18", "last_synced_at": "2026-10-20T12:46:31.584Z", "location_count": 2, "location_summary": "Gainesville, Georgia • Knoxville, Tennessee", "locations": [ { "city": "Gainesville", "state": "Georgia" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03693300" }, { "nct_id": "NCT03184571", "title": "Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer Metastatic", "NSCLC Stage IV", "Adenocarcinoma of Lung" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Bemcentinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BerGenBio ASA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2017-10-02", "completion_date": "2022-10-27", "has_results": true, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-20T12:46:31.584Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • Milwaukee, Wisconsin", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03184571" }, { "nct_id": "NCT02231164", "title": "LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2014-10-14", "completion_date": "2015-12-24", "has_results": true, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-10-20T12:46:31.584Z", "location_count": 9, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Highland, California + 6 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Highland", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Paducah", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02231164" }, { "nct_id": "NCT02364999", "title": "A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Bevacizumab-Pfizer", "type": "DRUG" }, { "name": "Bevacizumab-EU", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 719, "start_date": "2015-04", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2019-02-07", "last_synced_at": "2026-10-20T12:46:31.584Z", "location_count": 19, "location_summary": "Daphne, Alabama • Mobile, Alabama • Highland, California + 12 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Highland", "state": "California" }, { "city": "New Britain", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02364999" }, { "nct_id": "NCT04984811", "title": "NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Non-Small Cell Lung Cancer", "Non-Small Cell Lung Carcinoma", "Nonsmall Cell Lung Cancer", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "efineptakin alfa", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeoImmuneTech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2021-11-15", "completion_date": "2024-09-19", "has_results": true, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-20T12:46:31.584Z", "location_count": 22, "location_summary": "Mobile, Alabama • Cerritos, California • Norwich, Connecticut + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04984811" }, { "nct_id": "NCT00063895", "title": "Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-09", "last_synced_at": "2026-10-20T12:46:31.584Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00063895" }, { "nct_id": "NCT04629300", "title": "Supportive Care Mobile Application for Patients With NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non Small Cell Lung Cancer", "Quality of Life", "Coping Skills" ], "interventions": [ { "name": "Supportive Care Mobile Application", "type": "BEHAVIORAL" }, { "name": "Usual Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2021-10-15", "completion_date": "2024-07-31", "has_results": false, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-10-20T12:46:31.584Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Danvers, Massachusetts • Milford, Massachusetts + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Danvers", "state": "Massachusetts" }, { "city": "Milford", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629300" } ] }